13:51 EDT Cassava sinks 36% to $12.16 after DOJ charges co-developer of drug
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Largest borrow rate increases among liquid names
- Cassava receives patent allowance for Alzheimer’s disease assay
- Cassava Sciences call volume above normal and directionally bullish
- Cassava Sciences price target raised to $131 from $124 at H.C. Wainwright
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam